13,509 Humana Inc. $HUM Shares Sold by Allianz SE

Allianz SE lessened its position in Humana Inc. (NYSE:HUM – Free Report) by 75.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,351 shares of the insurance provider’s stock after selling 13,509 shares during the quarter. Allianz SE’s holdings in Humana were worth $1,660,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of HUM. Rothschild Investment LLC raised its position in Humana by 9.4% in the third quarter. Rothschild Investment LLC now owns 279 shares of the insurance provider’s stock worth $106,000 after purchasing an additional 24 shares in the last quarter. Pinnacle Wealth Planning Services Inc. grew its position in shares of Humana by 21.8% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 151 shares of the insurance provider’s stock worth $58,000 after buying an additional 27 shares during the period. Wilkerson Advisory Group LLC increased its holdings in Humana by 24.6% in the second quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider’s stock valued at $66,000 after purchasing an additional 33 shares during the last quarter. Moors & Cabot Inc. lifted its stake in Humana by 4.3% in the third quarter. Moors & Cabot Inc. now owns 804 shares of the insurance provider’s stock valued at $307,000 after buying an additional 33 shares during the period. Finally, Cidel Asset Management Inc. raised its position in shares of Humana by 1.1% in the 2nd quarter. Cidel Asset Management Inc. now owns 3,883 shares of the insurance provider’s stock valued at $1,542,000 after acquiring an additional 41 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Joseph Ventura sold 5,495 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the sale, the insider directly owned 21,910 shares of the company’s stock, valued at $9,505,653.50. This trade represents a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.20% of the company’s stock.

Humana News Roundup

These are some of the HUM news items that stood out recently:

  • Neutral Sentiment: Humana is up more than 50% this year, but investors who bought three years ago remain underwater. The durability of the recovery may depend on Medicare Advantage growth, Star Ratings and the company’s December investor update. 247WallSt article
  • Negative Sentiment: Zacks Research trimmed its Q3 2028 EPS estimate to $6.38 from $6.58, tempering the positive estimate revisions elsewhere. MarketBeat analyst estimates
  • Negative Sentiment: Healthcare insurers came under pressure amid a new Medicare for All proposal. Separately, a proposed CMS anti-fraud rule and a notice of an investigation into Humana’s disclosures around Medicare Advantage audit and repayment risk add policy and regulatory uncertainty. MarketWatch article Benzinga article

Humana Price Performance

Shares of Humana stock opened at $389.98 on Friday. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $46.84 billion, a price-to-earnings ratio of 37.94, a price-to-earnings-growth ratio of 1.87 and a beta of 0.65. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $462.87. The company has a 50-day simple moving average of $409.49 and a two-hundred day simple moving average of $322.39.

Humana (NYSE:HUM – Get Free Report) last released its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.30. The firm had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company’s revenue was up 26.1% compared to the same quarter last year. During the same period in the prior year, the company posted $3.24 EPS. Humana has set its FY 2026 guidance at 9.500- EPS. Analysts forecast that Humana Inc. will post 9.64 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be paid a $0.8850 dividend. The ex-dividend date is Thursday, December 24th. This represents a $3.54 annualized dividend and a dividend yield of 0.9%. Humana’s dividend payout ratio (DPR) is presently 34.44%.

Analyst Ratings Changes

A number of research firms have issued reports on HUM. Raymond James Financial reissued an “outperform” rating on shares of Humana in a research note on Friday, November 6th. Royal Bank Of Canada set a $515.00 target price on Humana in a report on Tuesday. Zacks Research upgraded shares of Humana from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 10th. KeyCorp lowered shares of Humana from an “overweight” rating to a “sector weight” rating in a research report on Monday, November 16th. Finally, Guggenheim increased their target price on shares of Humana from $471.00 to $521.00 and gave the stock a “buy” rating in a report on Monday, November 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $491.74.

Read Our Latest Research Report on Humana

About Humana

(Free Report)

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

See Also

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.